Retzer, Ameeta http://orcid.org/0000-0002-4156-8386
Ciytak, Bircan
Khatsuria, Foram
El-awaisi, Juma
Harris, Isobel M. http://orcid.org/0000-0001-8125-3832
Chapman, Laura
Kelly, Tony
Richards, Jenny
Lam, Emily
Newsome, Philip N. http://orcid.org/0000-0001-6085-3652
Calvert, Melanie http://orcid.org/0000-0002-1856-837X
El-awaisi, Juma
Filer, Andrew
Shetty, Shishir
Parish, Jo
Watson, Steve
Sapey, Elizabeth
Gillet, Caroline
Palmer, Jo
Yonel, Zehra
Miah, Zohur
Alderman, Joseph
Laws, Elinor
Liu, Xiaoxuan
,
Funding for this research was provided by:
DH | National Institute for Health Research (NIHR203326, NIHR203326, NIHR203326, NIHR203326, NIHR203326, NIHR203326, NIHR203326, NIHR203326, NIHR203326, NIHR203326)
Article History
Received: 12 April 2023
Accepted: 24 October 2023
First Online: 8 December 2023
Competing interests
: A.R.—funder: NIHR Birmingham BRC, NIHR Applied Research Collaboration West Midlands (ARC WM); funding: Birmingham City Council, UK Research and Innovation (UKRI). B.C.—funder: NIHR Birmingham BRC. F.K.—funder: NIHR Birmingham BRC. J.E.—funder: NIHR Birmingham BRC. I.M.H.—funder: NIHR. L.C.—funder: NIHR Birmingham BRC. T.K.—funder: NIHR Birmingham BRC. J.R.—funder: NIHR Birmingham BRC. E.L.—funder: NIHR Birmingham BRC. P.N.N.—funder: research support from NIHR Birmingham BRC (specific role: none); employment: University of Birmingham (professor of experimental hepatology, director of research and knowledge transfer in the College of Medical & Dental Sciences, director of the NIHR Birmingham BRC, honorary consultant hepatologist at University Hospitals Birmingham NHS Foundation Trust); personal financial interests: grants/contracts, Novo Nordisk; honoraria/travel reimbursement for attending conferences, educational writing: Novo Nordisk, AiCME; consultation fees/advisory boards: Novo Nordisk, Boehringer Ingelheim, Gilead, Intercept, Poxel Pharmaceuticals, BMS, Pfizer, Sun Pharma, Madrigal, GSK. M.C.—director of Birmingham Health Partners Centre for Regulatory Science and Innovation, director of Centre for Patient Reported Outcomes Research, NIHR senior investigator; funding: NIHR, UKRI, NIHR Birmingham BRC, NIHR ARC WM, UK SPINE, European Regional Development Fund DEMAND Hub, Health Data Research UK at the University of Birmingham, University Hospitals Birmingham NHS Foundation Trust, Innovate UK (part of UKRI), Macmillan Cancer Support, UCB Pharma, Janssen, GlaxoSmithKline, Gilead; personal fees: Astellas, Aparito, CIS Oncology, Halfloop, Takeda, Merck, Daiichi Sankyo, Glaukos, GlaxoSmithKline, Patient-Centered Outcomes Research Institute. A relative owns GlaxoSmithKline shares.